NCCN CNS tumor guidelines update for 2023.
作者信息
Nabors Burt, Portnow Jana, Hattangadi-Gluth Jona, Horbinski Craig
机构信息
Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Department of Medical Oncology and Research Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
出版信息
Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.
Abstract
摘要
相似文献
1
NCCN CNS tumor guidelines update for 2023.2023年美国国立综合癌症网络（NCCN）中枢神经系统肿瘤指南更新
Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.
2
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.中枢神经系统癌症，第 3.2020 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052.
3
Central Nervous System Cancers, Version 1.2015.中枢神经系统癌症，第 1.2015 版。
J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. doi: 10.6004/jnccn.2015.0148.
4
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.NCCN 指南®洞察：中枢神经系统肿瘤，第 2.2022 版。
J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002.
5
Guidelines in the management of CNS tumors.中枢神经系统肿瘤的治疗指南。
J Neurooncol. 2021 Feb;151(3):345-359. doi: 10.1007/s11060-020-03530-8. Epub 2021 Feb 21.
6
NCCN Guidelines(R) Updates.美国国立综合癌症网络（NCCN）指南更新
J Natl Compr Canc Netw. 2013 Sep 1;11(9):xxxii-xxxvi.
7
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.儿童中枢神经系统肿瘤，2023 年第 2 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. doi: 10.6004/jnccn.2022.0062.
8
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).评估临床试验中中枢神经系统成像偏离 NCCN 指南建议的比率，这些临床试验构成了一线晚期非小细胞肺癌 (NSCLC) 药物批准的基础。
BMC Cancer. 2022 Jan 16;22(1):70. doi: 10.1186/s12885-022-09179-y.
9
Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.将基因组学整合到神经肿瘤学临床试验与实践中。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989.
10
[The First Step in a Long-Run-Celebrating the announcement of "Guideline for the management of CNS gliomas in China"].[漫长征程的第一步——庆祝《中国中枢神经系统胶质瘤诊疗指南》发布]
Zhonghua Yi Xue Za Zhi. 2013 Aug 20;93(31):2417.
引用本文的文献
1
Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.脑肿瘤患者使用地塞米松：一项真实世界的药物警戒审计
Front Neurol. 2025 Aug 20;16:1632231. doi: 10.3389/fneur.2025.1632231. eCollection 2025.
2
Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.放疗对世界卫生组织一级脑膜瘤术后残留的影响。
J Clin Med. 2025 Aug 18;14(16):5829. doi: 10.3390/jcm14165829.
3
Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort Study.原发性中枢神经系统淋巴瘤放疗后的临床预测因素及复发特征：一项回顾性队列研究
Cancers (Basel). 2025 Jun 27;17(13):2176. doi: 10.3390/cancers17132176.
4
Editorial: Clinical therapy of brain tumors.社论：脑肿瘤的临床治疗
Front Neurol. 2025 May 23;16:1610463. doi: 10.3389/fneur.2025.1610463. eCollection 2025.
5
Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland): Study of Incidence, Management and Outcomes.瑞士日内瓦州泌尿生殖系统癌症脑转移：发病率、治疗及预后研究
Cancers (Basel). 2024 Oct 10;16(20):3437. doi: 10.3390/cancers16203437.
6
Current challenges in the treatment of gliomas: The molecular era.胶质瘤治疗中的当前挑战：分子时代
World J Clin Oncol. 2024 Aug 24;15(8):982-986. doi: 10.5306/wjco.v15.i8.982.
7
Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).立体定向体部放疗治疗脊柱寡转移瘤：意大利临床肿瘤学会和放射治疗学会（AIRO）的实践模式调查。
Clin Exp Metastasis. 2024 Oct;41(5):679-685. doi: 10.1007/s10585-024-10304-3. Epub 2024 Aug 1.
8
MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化是高级别胶质瘤进展后生存的一个强有力的预后因素。
Chin Neurosurg J. 2024 Jul 24;10(1):24. doi: 10.1186/s41016-024-00375-2.
9
Treatment of IDH-mutant glioma in the INDIGO era.INDIGO时代IDH突变型胶质瘤的治疗
NPJ Precis Oncol. 2024 Jul 19;8(1):149. doi: 10.1038/s41698-024-00646-2.
10
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.低级别胶质瘤管理的最新进展：异柠檬酸脱氢酶的启示及其他。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431450. doi: 10.1200/EDBK_431450.
本文引用的文献
1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.辅助和同步替莫唑胺治疗1p/19q未共缺失的间变性胶质瘤（CATNON；欧洲癌症研究与治疗组织26053-22054研究）：一项随机、开放标签的3期研究的第二次中期分析
Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.
3
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
4
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.信函：何时少即是多：脑肿瘤的地塞米松给药剂量
Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186.
Zotero 插件